Mean outcome (95% CI)b
|
Primary outcome
|
Change in HbA1c (pp)c
| -2.26pp (-2.99 to -1.53) | -1.44pp (-2.34 to -0.54) | -0.82pp (-1.86 to 0.21); 0.11 | -0.57pp (-1.44 to 0.29); 0.17 |
Secondary outcomes
|
Adherenced
| 75.64% (45.56 to 105.71%) | 36.29% (3.9 to 68.67%) | 39.35pp (-0.02 to 78.73); 0.0501 | 36.06pp (-0.78 to 72.9); 0.054 |
Glycaemic controle
| 45.04% (32.48 to 57.6%) | 34.86% (16.15 to 53.57%) | 10.18pp (-10.21 to 30.57); 0.29 | 10.87pp (-7.92 to 29.67); 0.23 |
Change in SBP (mmHg)c
| 2.33 (-0.1 to 4.76) | 1.47 (-4.32 to 7.26) | 0.86 (-5.05 to 6.77); 0.75 | 1.3 (-3.41 to 6.01); 0.56 |
Change in DBP (mm Hg)c
| 2.81 (-1.04 to 6.66) | 0.68 (-4.34 to 5.69) | 2.13 (-3.54 to 7.81); 0.43 | 0.29 (-1.93 to 2.51); 0.78 |
Hypertension controlf
| 73.2% (61.92 to 84.49%) | 72.47% (59.36 to 85.58%) | 0.73pp (-14.71 to 16.17); 0.92 | 0.0pp (-12 to 12.95); 0.93 |
Change in total serum cholesterol (mg/dL)c
| -5.24 (-19.82 to 9.34) | 2.75 (-5.73 to 11.22) | -7.99 (-23.43 to 7.45); 0.27 | -5.79 (-20.22 to 8.65); 0.4 |